| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Immunohematology and Bloodbank, Leiden University Medical Center, The Netherlands;
Department of Ophthalmology, Leiden University Medical Center, The Netherlands; and
Virogenetics Corporation, Troy, NY 12180
HLA-A*0201-restricted CTL against human gp100 were isolated from HLA-A*0201/Kb (A2/Kb)-transgenic mice immunized with recombinant canarypox virus (ALVAC-gp100). These CTL strongly responded to the gp100154–162 epitope, in the context of both the chimeric A2/Kb and the wild-type HLA-A*0201- molecule, and efficiently lysed human HLA-A*0201+, gp100+ melanoma cells in vitro. The capacity of the CTL to eradicate these tumors in vivo was analyzed in A2/Kb-transgenic transgenic mice that had received a tumorigenic dose of human uveal melanoma cells in the anterior chamber of the eye. This immune-privileged site offered the unique opportunity to graft xenogeneic tumors into immunocompetent A2/Kb-transgenic mice, a host in which they otherwise would not grow. Importantly, systemic (i.v.) administration of the A2/Kb-transgenic gp100154–162-specific CTL resulted in rapid elimination of the intraocular uveal melanomas, indicating that anti-tumor CTL are capable of homing to the eye and exerting their tumoricidal effector function. Flow cytometry analysis of ocular cell suspensions with HLA-A*0201-gp100154–162 tetrameric complexes confirmed the homing of adoptively transferred CTL. Therefore, the immune-privileged state of the eye permitted the outgrowth of xenogeneic uveal melanoma cells, but did not protect these tumors against adoptive immunotherapy with highly potent anti-tumor CTL. These data constitute the first direct indication that immunotherapy of human uveal melanoma may be feasible.
This article has been cited by other articles:
|
|
 |
|
  W. Yang, P. W. Chen, H. Li, H. Alizadeh, and J. Y. Niederkorn PD-L1: PD-1 Interaction Contributes to the Functional Suppression of T-Cell Responses to Human Uveal Melanoma Cells In Vitro Invest. Ophthalmol. Vis. Sci., June 1, 2008; 49(6): 2518 - 2525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Peng, E. Ko, W. Luo, X. Wang, P. A. Shrikant, and S. Ferrone CD4-Dependent Potentiation of a High Molecular Weight-Melanoma-Associated Antigen-Specific CTL Response Elicited in HLA-A2/Kb Transgenic Mice J. Immunol., February 15, 2006; 176(4): 2307 - 2315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. R. Alexander Jr., S. K. Libutti, J. F. Pingpank, S. M. Steinberg, D. L. Bartlett, C. Helsabeck, and T. Beresneva Hyperthermic Isolated Hepatic Perfusion Using Melphalan for Patients with Ocular Melanoma Metastatic to Liver Clin. Cancer Res., December 15, 2003; 9(17): 6343 - 6349. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. S. Missotten, J. G. J.-d. Korver, D. de Wolff-Rouendaal, J. E. Keunen, R. O. Schlingemann, and M. J. Jager Heat Shock Protein Expression in the Eye and in Uveal Melanoma Invest. Ophthalmol. Vis. Sci., July 1, 2003; 44(7): 3059 - 3065. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. E. Touloukian, W. W. Leitner, P. F. Robbins, S. A. Rosenberg, and N. P. Restifo Mining the Melanosome for Tumor Vaccine Targets: P.polypeptide Is a Novel Tumor-associated Antigen Cancer Res., November 1, 2001; 61(22): 8100 - 8104. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
